Table 2.
Ongoing Therapeutic Clinical Trials in Adult sALCL in the First Line Setting
| Diseases Studied | Brief Description | Study Design | Study Drugs | Primary Endpoint | Recruitment Status | Location | NCT Number |
|---|---|---|---|---|---|---|---|
| PTCL | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Patients With PTCL | Phase 2; Open-label | CEOP Alternating Pralatrexate | CR rate | Active, Not Recruiting | United States | NCT01336933 |
| CD30+ mature T-cell and NK-cell lymphomas | BV Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30 + Mature T-Cell and NK-Cell Neoplasms | Phase 1; Open-label | BV/CH-P; BV→CHOP | Safety | Active, Not Recruiting | United States, United Kingdom | NCT01309789 |
| CD30+ mature T-cell lymphoma | BV and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T- cell Lymphomas | Phase 3; Double-blind | BV/CHP CHOP | PFS | Recruiting | International | NCT01777152 |
| DLBCL, gray zone lymphoma, FL grade IIIB, PTCL, Burkitt lymphoma. | Dose-Adjusted EPOCH and Rituximab in Adults and Children With Previously Untreated Aggressive NHL | Phase 2; Open-label | DA-EPOCH + Rituximab | Overall response and PFS | Recruiting | United States | NCT00001337 |
| PTCL; PTCL, NOS; AITL; ALK− ALCL | Romidepsin in Combination With CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal PTCL | Phase 1/2; Open-label | Romidepsin + CHOEP | MTD, PFS | Recruiting | Italy | NCT02223208 |
| All PTCL | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated PTCL | Phase 2; Open-label | Romidepsin + Lenalidomide | ORR | Recruiting | United States | NCT02232516 |
| ALK+ ALCL | Efficacy and safety of crizotinib combined with CHOP chemotherapy for patients with ALK+ ALCL. | Open-label, NR | Crizotinib + CHOP | CR rate Safety/Efficacy | Recruiting | Multicenter, China | NCT02487316 |
Abbreviations. AITL: angioimmunoblastic T-cell lymphoma; BV: brentuximab vedotin; CEOP: cyclophosphamide, etoposide, vincristine, and prednisone; CR: complete remission; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; MTD: maximum tolerated dose; NOS: not otherwise specified; NR: non-randomized; ORR: objective response rate; PFS: progression-free survival; PTCL: peripheral T-cell lymphoma; RR: relapsed/refractory. Data from ClinicalTrials.gov (accessed September 8, 2015).